MedTrace Logo

BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

NCT04196530 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-11-12

No results posted yet for this study

Summary

A Phase 1 Open-label Dose Escalation Study of BDB001 in Combination with Atezolizumab in Subjects with Advanced Solid Tumors

Conditions

  • Tumor, Solid

Interventions

DRUG

BDB001 (EIK1001)

BDB001 (EIK1001) is an immunotherapy agent.

DRUG

Atezolizumab

Atezolizumab is a is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab has an acceptable preclinical safety profile and is approved as an IV therapy for a variety of advanced malignancies.

Sponsors & Collaborators

  • Seven and Eight

    collaborator UNKNOWN

  • Eikon Therapeutics

    lead INDUSTRY

Principal Investigators

  • Harry Raftopoulos, MD · Eikon Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-21
Primary Completion
2024-07-31
Completion
2024-08-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04196530 on ClinicalTrials.gov